drugset / Trial / NCT04115319

A Study of the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia.

NCT04115319

RandomizedParallel-groupQuadruple-blindTreatment

Summary

A clinical study to evaluate the long-term safety and tolerability of an investigational drug in people with schizophrenia. This study is accepting male and female participants between 18 years old -65 years old who have been diagnosed with schizophrenia. This study will be conducted in approximately 50 study centers worldwide. The study will last approximately 57 weeks.

Timeline

Start
2019-11-21
Primary completion
2022-12-30
Completion
2022-12-30

Drugs

EvaluationDrugModalityDoseRoute
Comparator Quetiapine Small molecule 400 mg
Comparator Quetiapine Small molecule 600 mg
Comparator Quetiapine Small molecule 800 mg
Subject Ulotaront Small molecule 50 mg
Subject Ulotaront Small molecule 75 mg
Subject Ulotaront Small molecule 100 mg

Indications